Roberto E Favoni

Summary

Affiliation: National Cancer Research Institute
Country: Italy

Publications

  1. pmc Preclinical studies identify novel targeted pharmacological strategies for treatment of human malignant pleural mesothelioma
    Roberto E Favoni
    IRCCS A O U San Martino IST, Laboratory of Gene Transfer, Genoa, Italy
    Br J Pharmacol 166:532-53. 2012
  2. ncbi Gefitinib targets EGFR dimerization and ERK1/2 phosphorylation to inhibit pleural mesothelioma cell proliferation
    Roberto E Favoni
    Department of Oncologia Traslazionale, Lab Trasferimento Genico, Istituto Nazionale per la Ricerca sul Cancro IST Nord, B3, Rm18, Largo Rosanna Benzi, 10 16132 Genova, Italy
    Curr Cancer Drug Targets 10:176-91. 2010
  3. doi Combined chemotherapy with cytotoxic and targeted compounds for the management of human malignant pleural mesothelioma
    Roberto E Favoni
    Department of Translational Oncology Research, Gene Transfer Laboratory, National Cancer Institute, Largo Rosanna Benzi, 10 16132 Genoa, Italy
    Trends Pharmacol Sci 32:463-79. 2011
  4. ncbi Enhanced effectiveness of last generation antiblastic compounds vs. cisplatin on malignant pleural mesothelioma cell lines
    Alessandra De Cupis
    Department of Preclinical Oncology, Laboratory of Pharmacology, Istituto Nazionale per la Ricerca sul Cancro, Largo Rosanna Benzi, 10 16132 Genoa, Italy
    Eur J Pharmacol 473:83-95. 2003
  5. doi Preclinical strategies targeted at non-small-cell lung cancer signalling pathways with striking translational fallout
    Roberto E Favoni
    Department of Experimental Medicine, University of Genoa, Via Leon Battista Alberti, 2 c o Laboratory of Gene Transfer, IRCCS AOU San Martino IST, Largo Rosanna Benzi, 10 16132 Genoa, Italy
    Drug Discov Today 18:11-24. 2013

Collaborators

Detail Information

Publications5

  1. pmc Preclinical studies identify novel targeted pharmacological strategies for treatment of human malignant pleural mesothelioma
    Roberto E Favoni
    IRCCS A O U San Martino IST, Laboratory of Gene Transfer, Genoa, Italy
    Br J Pharmacol 166:532-53. 2012
    ....
  2. ncbi Gefitinib targets EGFR dimerization and ERK1/2 phosphorylation to inhibit pleural mesothelioma cell proliferation
    Roberto E Favoni
    Department of Oncologia Traslazionale, Lab Trasferimento Genico, Istituto Nazionale per la Ricerca sul Cancro IST Nord, B3, Rm18, Largo Rosanna Benzi, 10 16132 Genova, Italy
    Curr Cancer Drug Targets 10:176-91. 2010
    ..Finally, we propose that the formation of inactive EGFR dimers may contribute to the antitumoral activity of Gefitinib...
  3. doi Combined chemotherapy with cytotoxic and targeted compounds for the management of human malignant pleural mesothelioma
    Roberto E Favoni
    Department of Translational Oncology Research, Gene Transfer Laboratory, National Cancer Institute, Largo Rosanna Benzi, 10 16132 Genoa, Italy
    Trends Pharmacol Sci 32:463-79. 2011
    ..Detailed knowledge of molecular mechanisms of signal transduction and neoangiogenesis in hMPM should aid in the design and screening of other promising compounds such as more efficacious receptor tyrosine kinase inhibitors...
  4. ncbi Enhanced effectiveness of last generation antiblastic compounds vs. cisplatin on malignant pleural mesothelioma cell lines
    Alessandra De Cupis
    Department of Preclinical Oncology, Laboratory of Pharmacology, Istituto Nazionale per la Ricerca sul Cancro, Largo Rosanna Benzi, 10 16132 Genoa, Italy
    Eur J Pharmacol 473:83-95. 2003
    ....
  5. doi Preclinical strategies targeted at non-small-cell lung cancer signalling pathways with striking translational fallout
    Roberto E Favoni
    Department of Experimental Medicine, University of Genoa, Via Leon Battista Alberti, 2 c o Laboratory of Gene Transfer, IRCCS AOU San Martino IST, Largo Rosanna Benzi, 10 16132 Genoa, Italy
    Drug Discov Today 18:11-24. 2013
    ..Several new targeted compounds have evolved from preclinical to clinical settings to affect growth factor pathways of NSCLC, and their therapeutic implications will be reviewed and discussed here...